PortfoliosLab logoPortfoliosLab logo
SGMO vs. OM
Performance
Return for Risk
Dividends
Drawdowns
Volatility
Financials

Performance

SGMO vs. OM - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Sangamo Therapeutics, Inc. (SGMO) and Outset Medical, Inc. (OM). The values are adjusted to include any dividend payments, if applicable.

Loading graphics...

SGMO vs. OM - Yearly Performance Comparison


2026 (YTD)202520242023202220212020
SGMO
Sangamo Therapeutics, Inc.
-38.07%-58.82%87.74%-82.70%-58.13%-51.94%46.25%
OM
Outset Medical, Inc.
3.50%-77.72%-79.48%-79.05%-43.98%-18.91%-6.33%

Fundamentals

Market Cap

SGMO:

$87.84M

OM:

$68.42M

EPS

SGMO:

-$0.41

OM:

-$4.59

PS Ratio

SGMO:

1.97

OM:

0.57

Total Revenue (TTM)

SGMO:

$39.55M

OM:

$119.48M

Gross Profit (TTM)

SGMO:

$25.32M

OM:

$46.75M

EBITDA (TTM)

SGMO:

-$117.16M

OM:

-$67.79M

Returns By Period

In the year-to-date period, SGMO achieves a -38.07% return, which is significantly lower than OM's 3.50% return.


SGMO

1D
5.35%
1M
-39.50%
YTD
-38.07%
6M
-61.44%
1Y
-54.38%
3Y*
-47.13%
5Y*
-53.74%
10Y*
-27.19%

OM

1D
0.00%
1M
7.56%
YTD
3.50%
6M
-72.61%
1Y
-64.80%
3Y*
-75.95%
5Y*
-65.96%
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

SGMO vs. OM — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

SGMO
SGMO Risk / Return Rank: 1616
Overall Rank
SGMO Sharpe Ratio Rank: 1818
Sharpe Ratio Rank
SGMO Sortino Ratio Rank: 2323
Sortino Ratio Rank
SGMO Omega Ratio Rank: 2323
Omega Ratio Rank
SGMO Calmar Ratio Rank: 99
Calmar Ratio Rank
SGMO Martin Ratio Rank: 88
Martin Ratio Rank

OM
OM Risk / Return Rank: 1515
Overall Rank
OM Sharpe Ratio Rank: 1313
Sharpe Ratio Rank
OM Sortino Ratio Rank: 1717
Sortino Ratio Rank
OM Omega Ratio Rank: 1616
Omega Ratio Rank
OM Calmar Ratio Rank: 1313
Calmar Ratio Rank
OM Martin Ratio Rank: 1717
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

SGMO vs. OM - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Sangamo Therapeutics, Inc. (SGMO) and Outset Medical, Inc. (OM). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


SGMOOMDifference

Sharpe ratio

Return per unit of total volatility

-0.51

-0.63

+0.13

Sortino ratio

Return per unit of downside risk

-0.26

-0.62

+0.37

Omega ratio

Gain probability vs. loss probability

0.97

0.91

+0.05

Calmar ratio

Return relative to maximum drawdown

-0.87

-0.77

-0.10

Martin ratio

Return relative to average drawdown

-1.54

-1.22

-0.32

SGMO vs. OM - Sharpe Ratio Comparison

The current SGMO Sharpe Ratio is -0.51, which is comparable to the OM Sharpe Ratio of -0.63. The chart below compares the historical Sharpe Ratios of SGMO and OM, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Loading graphics...

Sharpe Ratios by Period


SGMOOMDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

-0.51

-0.63

+0.13

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

-0.51

-0.67

+0.16

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

-0.29

Sharpe Ratio (All Time)

Calculated using the full available price history

-0.16

-0.66

+0.49

Correlation

The correlation between SGMO and OM is 0.25, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


Dividends

SGMO vs. OM - Dividend Comparison

Neither SGMO nor OM has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

SGMO vs. OM - Drawdown Comparison

The maximum SGMO drawdown since its inception was -99.50%, roughly equal to the maximum OM drawdown of -99.67%. Use the drawdown chart below to compare losses from any high point for SGMO and OM.


Loading graphics...

Drawdown Indicators


SGMOOMDifference

Max Drawdown

Largest peak-to-trough decline

-99.50%

-99.67%

+0.17%

Max Drawdown (1Y)

Largest decline over 1 year

-69.70%

-85.12%

+15.42%

Max Drawdown (5Y)

Largest decline over 5 years

-98.05%

-99.65%

+1.60%

Max Drawdown (10Y)

Largest decline over 10 years

-99.06%

Current Drawdown

Current decline from peak

-99.48%

-99.60%

+0.12%

Average Drawdown

Average peak-to-trough decline

-83.93%

-68.62%

-15.31%

Ulcer Index

Depth and duration of drawdowns from previous peaks

39.13%

53.63%

-14.50%

Volatility

SGMO vs. OM - Volatility Comparison

Sangamo Therapeutics, Inc. (SGMO) has a higher volatility of 28.34% compared to Outset Medical, Inc. (OM) at 18.14%. This indicates that SGMO's price experiences larger fluctuations and is considered to be riskier than OM based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading graphics...

Volatility by Period


SGMOOMDifference

Volatility (1M)

Calculated over the trailing 1-month period

28.34%

18.14%

+10.20%

Volatility (6M)

Calculated over the trailing 6-month period

78.81%

91.73%

-12.92%

Volatility (1Y)

Calculated over the trailing 1-year period

108.44%

102.71%

+5.73%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

106.51%

98.80%

+7.71%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

95.01%

95.80%

-0.79%

Financials

SGMO vs. OM - Financials Comparison

This section allows you to compare key financial metrics between Sangamo Therapeutics, Inc. and Outset Medical, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.0050.00M100.00M150.00MAprilJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025AprilJulyOctober
14.23M
28.87M
(SGMO) Total Revenue
(OM) Total Revenue
Values in USD except per share items